Treatment Details – 13.1 months
|Patients: This phase 2 study involved 92 patients with malignant pleural mesothelioma. The majority (79%) were men. Their median age was 60, ranging from 27 to 78 years of age.|
Treatment: Patients were treated with a combination of chemotherapy and surgery, called an extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection. Cisplatin is the chemotherapy drug that was given.
Toxicity: Four of the treated patients died. One died within 30 days of the operation from organ failure after a heart attack. Three patients died during the time shortly after surgery while they were recovering in the hospital. Grade 4 toxicities included atrial fibrillation, thrombosis or embolism, respiratory failure, cardiac ischemia, kidney failure, and enteric fistula.
Results: The median overall survival was 13.1 months for the patients receiving the surgery treatment.
Correspondence: Dr. David Sugarbaker